FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1380-1388 May 23, 1996 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Theophylline has been a popular medication for asthma for over 50 years. However, the introduction of newer pharmacologic agents, concern about the toxicity of theophylline, and recommendations in widely disseminated guidelines have recently contributed to its decreased use. In this review we reassess the role of theophylline in the pharmacotherapy of asthma and specifically address three pivotal questions: What are the data justifying its continued use? What are its risks? What is its role in the treatment of patients with asthma?

History

Although first used as intravenous therapy for acute asthma¹ and then as an oral medication in fixed doses in . . . [Full Text of this Article]

Pharmacologic Actions

Molecular Mechanisms of Action

Comparison with Alternative Drugs

Intervention for Relief of Acute Symptoms

Maintenance Therapy for Chronic Asthma

Pharmacodynamics

Pharmacokinetics

Dosage

Precautions

Safety

Indications

The Future Role of Theophylline

Source Information

From the Department of Pediatrics, University of Iowa College of Medicine, Iowa City (M.W.), and the College of Pharmacy and Department of Pediatrics, College of Medicine, University of Florida, Gainesville (L.H.).

Address reprint requests to Dr. Weinberger at the Department of Pediatrics, University of Iowa Hospital, 200 Hawkins Dr., Iowa City, IA 52242-1083.

References

This article has been cited by other articles:

• The American Lung Association Asthma Clinical Rese, (2007). Clinical Trial of Low-Dose Theophylline and Montelukast in Patients with Poorly Controlled Asthma. Am. J. Respir. Crit. Care Med. 175: 235-242 [Abstract] [Full Text]  
• Rutten, J., van den Berg, B., van Gelder, T., van Saase, J. (2005). Severe theophylline intoxication: a delay in charcoal haemoperfusion solved by oral activated charcoal. Nephrol Dial Transplant 20: 2868-2869 [Full Text]  
• Chu, E. K., Drazen, J. M. (2005). Asthma: One Hundred Years of Treatment and Onward. Am. J. Respir. Crit. Care Med. 171: 1202-1208 [Abstract] [Full Text]  
• RuDusky, B. M. (2005). Aminophylline: Exploring Cardiovascular Benefits Versus Medical Malcontent. ANGIOLOGY 56: 295-304 [Abstract]  
• Benoehr, P., Krueth, P., Bokemeyer, C., Grenz, A., Osswald, H., Hartmann, J. T. (2005). Nephroprotection by Theophylline in Patients with Cisplatin Chemotherapy: A Randomized, Single-Blinded, Placebo-Controlled Trial. J. Am. Soc. Nephrol. 16: 452-458 [Abstract] [Full Text]  
• Inbe, H., Watanabe, S., Miyawaki, M., Tanabe, E., Encinas, J. A. (2004). Identification and Characterization of a Cell-Surface Receptor, P2Y15, for AMP and Adenosine. J. Biol. Chem. 279: 19790-19799 [Abstract] [Full Text]  
• Barr, R G., Rowe, B. H, Camargo, C. A Jr (2003). Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ 327: 643- [Abstract] [Full Text]  
• Foukas, L. C., Daniele, N., Ktori, C., Anderson, K. E., Jensen, J., Shepherd, P. R. (2002). Direct Effects of Caffeine and Theophylline on p110delta and Other Phosphoinositide 3-Kinases. DIFFERENTIAL EFFECTS ON LIPID KINASE AND PROTEIN KINASE ACTIVITIES. J. Biol. Chem. 277: 37124-37130 [Abstract] [Full Text]  
• Rabe, K.F., Schmidt, D.T. (2001). Pharmacological treatment of asthma today. Eur Respir J 18: 34S-40s [Abstract] [Full Text]  
• Bourdet, S. V., Williams, D. (2001). Management Considerations for Chronic Asthma. Journal of Pharmacy Practice 14: 108-125 [Abstract]  
• Beauchesne, M.-F. (2001). Management of Chronic Obstructive Pulmonary Disease: A Review. Journal of Pharmacy Practice 14: 126-142 [Abstract]  
• Hart, S.P. (2000). Should aminophylline be abandoned in the treatment of acute asthma in adults?. QJM 93: 761-765 [Abstract] [Full Text]  
• Miura, T., Kimura, K. (2000). Theophylline-Induced Convulsions in Children With Epilepsy. Pediatrics 105: 920-920 [Full Text]  
• Shannon, M. (1999). Life-Threatening Events After Theophylline Overdose: A 10-Year Prospective Analysis. Arch Intern Med 159: 989-994 [Abstract] [Full Text]  
• McConnell, S. A., Nafziger, A. N., Amsden, G. W. (1999). Lack of effect of dirithromycin on theophylline pharmacokinetics in healthy volunteers. J Antimicrob Chemother 43: 733-736 [Abstract] [Full Text]  
• CHEUNG, D., WEVER, A. M. J., de GOEIJ, J. A., de GRAAFF, C. S., STEEN, H., STERK, P. J. (1998). Effects of Theophylline on Tolerance to the Bronchoprotective Actions of Salmeterol in Asthmatics In Vivo. Am. J. Respir. Crit. Care Med. 158: 792-796 [Abstract] [Full Text]  
• Trépanier, E. F., Nafziger, A. N., Amsden, G. W. (1998). Effect of Terbinafine on Theophylline Pharmacokinetics in Healthy Volunteers. Antimicrob. Agents Chemother. 42: 695-697 [Abstract] [Full Text]  
• Feoktistov, I., Biaggioni, I. (1997). Adenosine A2B Receptors. Pharmacol. Rev. 49: 381-402 [Abstract] [Full Text]  
• Evans, D. J., Taylor, D. A., Zetterstrom, O., Chung, K. F., O'Connor, B. J., Barnes, P. J. (1997). A Comparison of Low-Dose Inhaled Budesonide plus Theophylline and High-Dose Inhaled Budesonide for Moderate Asthma. NEJM 337: 1412-1419 [Abstract] [Full Text]  
• Carlstedt, B. C. (1997). Pharmacotherapy of Asthma. Journal of Pharmacy Practice 10: 147-164 [Abstract]  
• Petty, T. L., Weinmann, G. G. (1997). Building a National Strategy for the Prevention and Management of and Research in Chronic Obstructive Pulmonary Disease: National Heart, Lung, and Blood Institute Workshop Summary. JAMA 277: 246-253 [Abstract]